Trial Profile

Phase 2 trial of MSC 2363318A in cancers associated with a high-prevalence of PAM mutations (Triple Negative Breast Cancer and Gastric Cancer)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 26 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rupitasertib (Primary) ; Elacestrant
Indications Advanced breast cancer; Gastric cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Therapeutic Use

22 Apr 2024 According to Evexta Bio media release, The phase 2 trial is expected to start enrolling patients in Q4/2024.
22 Apr 2024 According to Evexta Bio media release, Following a Type B meeting held on March 13, 2024, the U.S. Food and Drug Administration (FDA) provided Evexta Bio with valuable input on various aspects of rupitasertib development, including CMC, preclinical and clinical topics, enabling the company to proceed with the Phase 2 study in advanced breast cancer.
11 Jan 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com